
MindWalk
Victoria, BC, Canada mindwalkai.com
From their website, Nov 2026
Work here? Claim this listing
About
MindWalk is an antibody discovery company serving pharma, biotech, and academic partners. It provides end-to-end discovery, development, optimization, and protein production services for therapeutic, diagnostic, and research biologics from sites in the USA, Canada, and Belgium.
Services
Antibody discovery, development, and optimization
End-to-end antibody discovery from target analysis through optimized lead selection using wet-lab workflows and AI-enabled analysis.
Therapeutic antibody discovery
Function-first discovery and development of therapeutic antibodies selected for function, not just binding.
Anti-drug and anti-idiotype antibody discovery
Discovery of anti-drug and anti-idiotypic antibodies with reproducible data packages and validated assays.
Diagnostic antibody discovery
Discovery of diagnostic antibodies designed for high affinity, sensitivity, specificity, reproducibility, and scalable performance.
Research antibody discovery
Discovery of antibodies for research and analytical applications, including custom solutions for challenging targets.
Protein engineering, expression, and production
Design, expression, and production of recombinant proteins and antibody formats, from sequence to purified protein.
LensAI analysis
AI analysis for epitope mapping, paratyping, developability, immunogenicity, and candidate evaluation.
MindWalk Collaborative
Events, webisodes, and collaborative forums for biologics R&D.
Antibody discovery programs
End-to-end antibody discovery, development, and optimization customized to a target.
B cell Select® discovery
Functional antibody discovery platform with >98% discovery success rate stated by the company.
B cell Llama™ VHH discovery
Direct B cell VHH discovery platform for bispecific, multispecific, and other therapeutic formats.
Hybridoma discovery
Antibody discovery using hybridoma-based campaigns.
Yeast display discovery
Antibody discovery using yeast display.
Therapeutic antibodies
Discovery support for therapeutic antibody programs.
Anti-drug & anti-idiotype antibodies
Discovery and development support for anti-drug and anti-idiotype antibodies.
Diagnostic antibodies
Discovery and development support for diagnostic antibodies.
Protein engineering & production
Protein engineering and production services.
ReefIQ™
Biological context layer that connects discovery data and adds biological meaning for AI drug discovery.
LensAI™
AI analysis platform used in programs for epitope mapping, paratyping, developability, immunogenicity, and candidate evaluation.
- Turnaround
- From sequence to purified recombinant antibody: 3 weeks · 8-10 weeks for new custom proteins · B cell discovery: From immunization to delivery <12 weeks
Capabilities
- Assays and studies
- Antibodies · Hybridoma · Immunogenicity · Bispecifics · Epitope mapping · Paratyping · Developability assessment · Immunogenicity screening · Candidate evaluation · Binding affinity optimization · Target specificity assessment · Selectivity assessment
5 more
Western blot · IHC · Flow cytometry · Developability · Anti-drug-antibody risk prediction - Scale and capacity
- 100 µg–1 mg · 10–50 mg · Gram-scale production · Over 20 publicly disclosed client antibodies have entered the clinic · Ten in the clinic today · Four first in class · 3,000 times
- Therapeutic areas
- Oncology · Infectious disease · Neurodegeneration · Metabolic disease · Rare disease · Inflammation · Drug discovery
Instruments and platforms
- X-ray crystallography
Modalities and species
- Modalities
- Antibody · Bispecific · Peptide · Recombinant protein · Vaccine
- Species and models
- Rabbit · Chicken · Camelid · Mouse · HEK293 · CHO · E. coli · Camelid immune repertoire
Industries served
- Biotech
- Pharma
- Academic research
- Biologics
- Drug discovery
- Diagnostics
Company
- Type
- CRDMO
- Founded
- 2019
- Quality
- >98% discovery success rate (B cell Select® discovery success rate) · 100% success rate (anti-idiotypic antibody discovery to date) · #1 antibody discovery and development co (Roots Analysis (2022)) · LensAI won the 2024 InterSystems Impact (outperforming more than 1,000 global biotherapeutic research projects) · Patented HYFT® technology (EP3881326)
Locations
- Address
- 823 Congress Ave Suite 300 Austin, TX 78701, USA
- Sites
- Austin, USA · Fargo, USA · Victoria, Canada · Diepenbeek, Belgium
- Serves
- USA, Canada, Europe, global
Contacts
- Phone
- +1 (800) 620-4187
Public records
- Wikidata
- Q30282844 source
Similar labs
Work here? Claim this listing